Global Collaboration Aims to Conquer Buruli Ulcers: Australian Team Joins Forces with Johns Hopkins Medicine

We are excited to announce that our team has been awarded an Australian Global Connections Fund Bridging Grant to collaborate with international researchers in the fight against Buruli ulcers. This grant will allow us to partner with Mycobacterium expert Professor Eric Nuermberger at Johns Hopkins Medicine to explore the potential of our formulations against this debilitating disease.

Buruli ulcers is a neglected tropical disease that affects thousands of people each year, primarily in developing countries. There is currently no effective treatment for this disease, and it can cause serious disability or even death in severe cases. Our goal is to develop a new treatment that can effectively target the bacteria that cause these ulcers and promote healing in affected individuals.

As part of our collaboration with Eric Nuermberger and his team at Johns Hopkins Medicine, we will begin by conducting in vitro testing of our antimicrobial formulations to determine their efficacy against the Buruli ulcer-causing bacteria. We will then expand our research to animal models to further evaluate the safety and efficacy of our treatments.

This collaboration represents a significant step forward in our efforts to develop innovative treatments for skin diseases like Buruli ulcers. Eric Nuermberger and his team at Johns Hopkins Medicine are world-renowned experts in this field, and we are honored to be working with them to advance our research.

The Australian Global Connections Fund Bridging Grant will provide us with $50,000 to set up this collaboration and make significant progress in our research. We believe that our formulations have the potential to make a real difference in the lives of those affected by Buruli ulcers, and we are committed to bringing these treatments to market as quickly and safely as possible.

We are thrilled to have received this funding to collaborate with Eric Nuermberger and his team at Johns Hopkins Medicine to explore our formulations against Buruli ulcers. This collaboration represents a major step forward in our mission to develop innovative treatments for skin conditions, and we are excited to see the results of our research in the coming months.

For more information on Eric Nuermberger and his lab at Johns Hopkins Medicine, please visit the Johns Hopkins Medicine website. To learn more about Buruli ulcers and the impact of this disease, please visit the WHO website.